Filing Flows › Indivior Pharmaceuticals (INDV) › R&D spending
Indivior Pharmaceuticals (INDV) R&D spending by quarter
Indivior Pharmaceuticals' R&D spending was $5.0M in Q3 2026 (third quarter 2026), -58% from Q2 2026. Over the last 6 quarters it ranged from $5.0M (Q3 2026) to $33.0M (Q3 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $5.0M | -58% | -85% |
| Q2 2026 | $12.0M | -25% | — |
| Q1 2026 | $16.0M | -24% | -27% |
| Q4 2025 | $21.0M | -36% | — |
| Q3 2025 | $33.0M | +50% | — |
| Q1 2025 | $22.0M | — | — |
Q3 2026 at a glance
Indivior Pharmaceuticals, Q3 2026: revenue $356M (+13% year over year), operating margin 50.6%, net earnings $137M, operating cash flow $97.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Indivior Pharmaceuticals' R&D spending?
Indivior Pharmaceuticals' R&D spending was $5.0M in Q3 2026 (third quarter 2026), -58% from Q2 2026.
How has Indivior Pharmaceuticals' R&D spending changed?
Over the last 6 quarters it ranged from $5.0M (Q3 2026) to $33.0M (Q3 2025).
Q3 2026 results → · How Indivior Pharmaceuticals makes money →